PureTech Health (LON:PRTC) Insider Acquires 36,500 Shares

PureTech Health plc (LON:PRTC) insider Robert Lyne purchased 36,500 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was acquired at an average cost of GBX 119 per share, with a total value of £43,435.

PureTech Health Stock Performance

LON:PRTC opened at GBX 120 on Thursday. The company has a quick ratio of 2.51, a current ratio of 6.59 and a debt-to-equity ratio of 6.33. The firm’s fifty day simple moving average is GBX 129.88 and its 200 day simple moving average is GBX 127.13. The stock has a market cap of £292.10 million, a P/E ratio of -2.61 and a beta of 0.79. PureTech Health plc has a twelve month low of GBX 104.71 and a twelve month high of GBX 148.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.